Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 1070-1076

  Milas, Ivan ^a   Komaki, Ritsuko ^a   Hachiya, Tsutomu ^a   Bubb, Robbin S ^a   Ro, Jae Y ^a   Langford, Lauren ^a   Sawaya, Raymond ^a   Putnam, Joe B ^a   Allen, Pamela ^a   Cox, James D ^a   McDonnell, Timothy J ^a   Brock, William ^b   Hong, Waun Ki ^a   Roth, Jack A ^a   Milas, Luka ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BAX;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 0037341350     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA - Cancer J. Clin., 52: 23-47, 2002.
2. , Posner, J. B. Intracranial metastases. In: Neurologic Complications of Cancer, pp. 77. Philadelphia: F. A. Davis Co., 1995.
3. Robnett, T. J., Machtay, M., Stevenson, J. P., Algazy, K. M., and Hahn, S. M. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J. Clin. Oncol., 19: 1344-1349, 2001.
4. Pottgen, C., and Stuschke, M. The role of prophylactic cranial irradiation in the treatment of lung cancer. Lung Cancer, 33 (Suppl. 1): S153-S158, 2001.
5. Komaki, R., Cox, J. D., and Whitson, W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat. Rep., 65: 811-814, 1981.
6. Borgelt, B., Gelber, R., Kramer, S., Brady, L. W., Chang, C. H., Davis, L. W., Perez, C. A., and Hendrickson, F. R. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys., 6: 1-9, 1980.
7. Stuschke, M., Eberhardt, W., Pöttgen, C., Stamatis, G., Wilke, H., Stüben, G., Stöblen, F., Wilhelm, H. H., Menker, H., Teschler, H., Müller, R-D., Budach, V., Seeber, S., and Sack, H. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J. Clin. Oncol., 17: 2700-2709, 1999.
8. Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission (Cochrane Review). Cochrane Database Syst. Rev., Vol. 4, 2000.
9. Auperin, A., Arriagada, R., Pignon, K-P., Le Pechoux, C., Gregor, A., Stephens, R. J., Kristjansen, E. G., Johnson, B. E., Ueoka, H., Wagner, H., and Aisner, J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med., 341: 476-484, 1999.
10. Arnold, S. M., Young, A. B., Munn, R. K., Patchell, R. A., Hanayakkara, U., and Markesbery, W. R. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metallo-proteinases-1 in paired primary tumors and brain metastasis. Clin. Cancer Res., 5: 4028-4033, 1999.
11. D'Amico, T. A., Aloia T. A., Moore, M-B. H., Conlon, D. H., Herndon, J. E., II, Kinch, M. S., and Harpole, Jr., D. H. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann. Thorac. Surg., 72: 1144-11448, 2001.
12. Nicholson, R. I., Gee, J. M., and Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer, 37 (Suppl. 4): S9-S15, 2001,
13. Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K., Nakamura, S., Ogawa, M., Mitsudomi, T., Sugiura, T., and Takahashi, T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 58: 3761-3764, 1998.
14. Wolff, H., Saukkomen, K., Auttila, S., Karjalainen, A., Vainio, H., and Ristimäki, A, Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58: 4997-5001, 1998.
15. Achiwa, H., Yatabe, Y., Hida, T., Kuroishi, T., Kozaki, K., Nakamura, W., Ogawa, M., Sugiura, T., Mitsudomi, T., and Takahashi, T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res., 5: 1001-1005, 1999.
16. Krajewski, S., Krajewski, M., Shabaik, A., Mujoshita, T., Wang, H. G., and Reed, J. C. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am. J. Pathol., 145: 1323-1336, 1994.
17. Rusch, V., Klimstra, D., Venkatraman, E., Pisters, P. W. T., Langenfeld, J., and Dmitrovsky, E, Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res., 3: 515-522, 1997.
18. Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner B. M., Khan, K. N., Mosferrer, J., and Koki, A. T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer (Phila.), 89: 2637-2645, 2000.
19. Huang, C., Kohno, N., Inufusa, H., Kodama, K., Taki, T., and Miyake, M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am. J. Pathol., 155: 955-965, 1999.
20. Ohsaki, Y., Tamo, S., Fujita, Y., Toyoshima, E., Fujiuchi, S., Nishigski, Y., Ishida, S., Nagase, A., Miyokawa, N., Hirata, S., and Kikuchi, K. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 over-expression. Oncol. Rep., 7: 603-607, 2000.
21. Caputi, M., Groeger, A. M., Esposito, V., De Luca, A., Murabito, M., Tahir, T., Gordano, G. G., Baldi, F., Girodano, A., and Wolner, E. Frequent high expression of bax pro-apoptotic protein in non-small cell lung cancer. Anticancer Res., 19: 825-827, 1999.
22. Apolinario, R. M., van der Valk, P., de Jong, J. S., Deville, W., van Ark-Otte, J., Dingemans, A-M. C., van Mourik, J. C., Postmus, P. E., Pinedo, H. M., and Giaccone, G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J. Clin. Oncol., 15: 2456-2466, 1997.
23. Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med., 3: 614-620, 1997.